Of the two RCTs evaluated by de Thurah et al. that reported both 1- and 2-year disease activity data, Primdahl et al. reported no significant difference in disease activity (primary endpoint; per DAS28-4 [CRP]) in patients with RA receiving NLC versus PLC at 12 months, but found NLC to be significantly superior at 24 months (P = 0.049) [24]. The gene discussed is CRP; the disease is rheumatoid arthritis.